(Q33434752)

6 October 2017

A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas (English)

1 reference

6 October 2017

Jeffrey R Infante

1

1 reference

6 October 2017

Philippe A Cassier

2

1 reference

6 October 2017

John F Gerecitano

3

1 reference

6 October 2017

Petronella O Witteveen

4

1 reference

6 October 2017

Rashmi Chugh

5

1 reference

6 October 2017

Vincent Ribrag

6

1 reference

6 October 2017

Abhijit Chakraborty

7

1 reference

6 October 2017

Alessandro Matano

8

1 reference

6 October 2017

Jason R Dobson

9

1 reference

6 October 2017

Adam S Crystal

10

1 reference

6 October 2017

Sudha Parasuraman

11

1 reference

6 October 2017

Geoffrey I Shapiro

12

1 reference

6 October 2017

language of work or name

English

0 references

publication date

19 August 2016

1 reference

6 October 2017

Clinical Cancer Research

1 reference

6 October 2017

22

1 reference

6 October 2017

23

1 reference

6 October 2017

5696-5705

1 reference

Targeting CDK4 and CDK6: From Discovery to Therapy

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5621377

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5621377

The history and future of targeting cyclin-dependent kinases in cancer therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5621377

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5621377

Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5621377

Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5621377

Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5621377

CDK4: A Key Player in the Cell Cycle, Development, and Cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5621377

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5621377

Cyclin-dependent kinase pathways as targets for cancer treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5621377

Cyclin D-dependent kinases, INK4 inhibitors and cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5621377

Update on the therapeutic potential of PDE4 inhibitors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5621377

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5621377

Role of the p16 tumor suppressor gene in cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5621377

Critical aspects of the Bayesian approach to phase I cancer trials.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5621377

Revised response criteria for malignant lymphoma

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5621377

10.1158/1078-0432.CCR-16-1248

31 October 2018

Identifiers

DOI

1 reference

6 October 2017

1 reference

6 October 2017

PubMed publication ID

27542767

1 reference